|
Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB) Clinical Trials Data presented on Clinical Trials Search is not meant to be a substitute for qualified health advice, visits or treatment with a real mD. We are not doctors. Always consult your doctor about Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB) conditions. Clinical Trials Search.org is a site devoted to listing clinical research studies in human subjects. Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB) Clinical research trials and Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB) healthcare trials happen in many of places across the United States. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally assess the effectivity of new drugs. The purpose of the studies / projects is to solve particular human medical questions. Clinical trials are a popular way for doctors, government agencies, and private sector companies to discover cures for all varieties of conditions, such as Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB). Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB) Clinical Trials and other clinical trials allow volunteers to have health treatment alternatives before they are available to the masses. Some times the human subjects obtain treatment for without cost, and sometimes they are compensated for their time. Occasionally there is a cost for a Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB) clinical trial. Test subjects oftentimes receive the most effective healthcare possible for their Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB) condition. Dangers are a reality, however, and may include extra or frequent physician visits, healthcare dangers (possibly life-jeopardising), and/or the treatment being uneffective. Trials are federally governed with rigorous guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "C" Clinical Trials Conditions > Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)  Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)
Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)
For Condition: Cardiovascular Disease,Coronary Artery Bypass Surgery
Status: Recruiting
Sponsor(s): The Medicines Company ,
Synopsis: The purpose of this study is to demonstrate that in patients undergoing coronary artery bypass grafting (CABG) or CABG-Valve, or Isolated Cardiac Valve surgery on CPB, Angiomax is a safe and effective alternative anticoagulant to heparin with protamine reversal.
Details:
Eligibility:
Study Type: Interventional, Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - Provide written informed consent before initiation of any study related procedures. - Be at least 18 years of age. - Be scheduled for CABG, CABG and single valve surgery, or isolated single valve surgery on CPB. Patients undergoing repeat (redo) CABG are also considered eligible for this study. Exclusion Criteria - Confirmed pregnancy at time of randomization via IVRS (if woman of child-bearing potential) (Urine or serum pregnancy test) - Cerebrovascular accident within 6 months, or any cerebrovascular accident with a residual neurological deficit. - Intracranial neoplasm, arteriovenous malformation or aneurysm. - Dependency on renal dialysis or creatinine clearance <30 mL/min. - Ongoing treatment with warfarin (or other oral anticoagulant) at the time of randomization. Patients previously treated with warfarin may be enrolled if warfarin therapy can be safely discontinued and baseline INR is < 1.3 times control in the absence of heparin therapy. - Known allergy to Angiomax or hirudin-derived drugs, or known sensitivity to any component of the product. - Patients receiving clopidogrel (Plavix®) within the previous 5 days of randomization - Patients receiving a glycoprotein IIb/IIIa inhibitor within the previous 48 hours if abciximab (ReoPro®) or 24 hours if eptifibatide (Integrilin®) or tirofiban (Aggrastat®) of randomization. - Patients receiving lepirudin (Refludan®) or argatroban within the previous 24 hours prior to randomization. - Patients receiving LMWH or thrombolytics within the previous 12 hours or unfractionated heparin within 30 minutes of randomization. - Participation in other clinical research studies involving the evaluation of other investigational drugs or devices within 30 days of randomization. - Refusal to undergo blood transfusion should it become necessary. - Any other disease or condition, which, in the judgment of the Investigator, would place a patient at undue risk by being enrolled in the trial, or cause inability to comply with the trial. - Planned surgical procedure in which proximal anastomoses will precede distal anastomoses of the bypass grafts. - Planned (>1) double (or greater) valve repair-replacement (e.g.: AVR-MVR) surgery.
Total Enrollment: 150
Location and Contact Information:
Overall Study Official:
MalcolmLloyd, Study Director, The Medicines Company
The Cleveland Clinic *Recruiting*
Cleveland, Ohio, 44195
United States
Recruiting Nicholas Smedira 216-444-2220
Additional Information:
Study ID Numbers: TMC-BIV-02-06; EVOLUTION-On
Study Start Date:
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00079586
Other Cardiovascular Disease Studies:
1. Comparing Angiomax to Heparin with Protamine Reversal in Patients OPCAB
2. Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)
3. Angiomax in Patients with HIT/HITTS Type II Undergoing CPB
Related Studies:
Other Cardiovascular Disease Clinical Trials
Other Ohio Clinical Trials
Other Cleveland Clinical Trials
Comparing Angiomax to Heparin with Protamine in Patients Undergoing Cardiopulmonary Bypass (CPB)
|
|
|
|
|
|
|
|
